Core Insights - Wuxi Heyou Biotechnology Co., Ltd. has completed a Pre-A round financing of several tens of millions of RMB [1] - The financing was led by Guolian Investment and Wuxi Xidong Industrial Investment Center, aimed at upgrading GMP-level products and accelerating global business expansion [1] - The company is entering a new phase of rapid development, focusing on enhancing product quality and capacity while strengthening its core advantages in domestic substitution [1] Financing Details - The financing amount is in the range of several tens of millions of RMB [1] - Investors include Guolian Investment's core market-oriented fund and Wuxi Xidong Industrial Investment Center [1] Business Strategy - Funds will be used to promote the iteration and upgrade of GMP-level products [1] - The company aims to deepen its international market presence by commercializing primary cells and related reagents and technical services globally [1] - There is a focus on improving the product matrix and reinforcing integrated solutions centered around primary cells [1]